The total return over the past 12 months is +88.73% vs. +16.94% for the S&P 500. So far it's up +27.06% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +88.73% | (41.69%) | (34.33%) | (11.05%) | (9.12%) | (6.75%) |
| Total Return CAGR | +88.73% | (41.69%) | (34.33%) | (11.05%) | (9.12%) | (6.75%) |
| Revenue CAGR | (1.06%) | (8.35%) | (4.62%) | (1.98%) | (1.46%) | +1.10% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | (132.37%) | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | (90.20%) | (57.88%) | (35.68%) | (10.20%) | (16.02%) | (11.37%) |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Harvard Bioscience, Inc. (HBIO)
| Year | Start price | End price | HBIO Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $6.69 | $8.50 | +27.06% | +14.51% | +12.55% |
| 2025 | $21.10 | $6.69 | (68.29%) | +17.72% | (86.01%) |
| 2024 | $53.50 | $21.10 | (60.56%) | +24.89% | (85.45%) |
| 2023 | $27.70 | $53.50 | +93.14% | +26.19% | +66.95% |
| 2022 | $70.50 | $27.70 | (60.71%) | (18.17%) | (42.54%) |
| 2021 | $42.90 | $70.50 | +64.34% | +28.74% | +35.60% |
| 2020 | $30.50 | $42.90 | +40.66% | +18.37% | +22.29% |
| 2019 | $31.80 | $30.50 | (4.09%) | +31.22% | (35.31%) |
| 2018 | $33.00 | $31.80 | (3.64%) | (4.56%) | +0.92% |
| 2017 | $30.50 | $33.00 | +8.20% | +21.70% | (13.50%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
